Ther Adv Endocrinol Metab. 2012 Feb;3(1):11-26. doi: 10.1177/2042018812437356.
Pheochromocytomas are rare endocrine tumors that can present insidiously and remain undiagnosed until death or onset of clear manifestations of catecholamine excess. They are often referred to as one of the 'great mimics' in medicine. These tumors can no longer be regarded as a uniform disease entity, but rather as a highly heterogeneous group of chromaffin cell neoplasms with different ages of onset, secretory profiles, locations, and potential for malignancy according to underlying genetic mutations. These aspects all have to be considered when the tumor is encountered, thereby enabling optimal management for the patient. Referral to a center of specialized expertise for the disease should be considered wherever possible. This is not only important for surgical management of patients, but also for post-surgical follow up and screening of disease in patients with a hereditary predisposition to the tumor. While preoperative management has changed little over the last 20 years, surgical procedures have evolved so that laparoscopic resection is the standard of care and partial adrenalectomy should be considered in all patients with a hereditary condition. Follow-up testing is essential and should be recommended and ensured on a yearly basis. Managing such patients must now also take into account possible underlying mutations and the appropriate selection of genes for testing according to disease presentation. Patients and family members with identified mutations then require an individualized approach to management. This includes consideration of distinct patterns of biochemical test results during screening and the appropriate choice of imaging studies for tumor localization according to the mutation and associated differences in predisposition to adrenal, extra-adrenal and metastatic disease.
嗜铬细胞瘤是罕见的内分泌肿瘤,其发病隐匿,在死亡或儿茶酚胺过多的明显表现出现之前,往往无法诊断。它们通常被称为医学中的“一大类模拟疾病”。这些肿瘤不能再被视为单一的疾病实体,而是根据潜在的基因突变,具有不同发病年龄、分泌谱、位置和恶性潜能的高度异质性嗜铬细胞肿瘤群。在遇到肿瘤时,所有这些方面都需要考虑,从而为患者提供最佳的管理。尽可能向专门的疾病中心转诊是必要的。这不仅对患者的手术管理很重要,而且对遗传性肿瘤患者的术后随访和疾病筛查也很重要。虽然术前管理在过去 20 年中变化不大,但手术方法已经发展,因此腹腔镜切除术已成为标准治疗方法,对于遗传性疾病患者,应考虑部分肾上腺切除术。随访检查至关重要,应每年推荐并确保进行。现在,管理此类患者还必须考虑可能存在的潜在突变,并根据疾病表现选择适当的基因进行检测。然后,确定突变的患者和家属需要个体化的管理方法。这包括在筛查期间考虑不同的生化检测结果模式,以及根据突变和相关的肾上腺外、转移性疾病易感性,选择适当的肿瘤定位成像研究。